Peru to test China Sinopharm's Covid-19 vaccine in Phase 3 trial
Coronavirus chronicle
20 August, 2020, 03:40 pm
Last modified: 20 August, 2020, 03:42 pm
The experimental vaccine of CNBG, a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), has already entered Phase 3 testing in United Arab Emirates
FILE PHOTO: The company logo of Sinopharm Group Co Ltd is displayed at a news conference on the company's annual results in Hong Kong, China March 29, 2016. REUTERS/Bobby Yip/File Photo
Health authorities of the Republic of Peru have approved a Phase 3 clinical trial for a potential Covid-19 vaccine developed by China National Biotec Group (CNBG), the company said on Thursday in Chinese social media platform Weibo.
The experimental vaccine of CNBG, a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), has already entered Phase 3 testing in United Arab Emirates.
Phase 3 trials, which usually involve several thousand participants, allow researchers to gather data on the efficacy of potential vaccines for final regulatory approvals.
Comments
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.